A Study of ARGX-110 in Participants With Advanced Malignancies
Status:
Completed
Trial end date:
2020-07-10
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the optimal dose of ARGX-110 in participants with
advanced malignancies and to assess efficacy of ARGX-110 (exploratory efficacy cohort 5
only).